Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Part cancer drug enters first human tests

NCT ID NCT06959706

Recruiting now Disease control Sponsor: Tagworks Pharmaceuticals BV Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and find the right dose, while also looking at how the drug moves through the body and whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TGW101 (a two-part drug: an antibody-drug conjugate and a chemical trigger)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 50 participants, focused mainly on safety. It is too soon to know if TGW101 will be effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer carcinoma castration-resistant prostate carcinoma cervical cancer endometrial cancer esophageal adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma head and neck carcinoma head and neck squamous cell carcinoma lung adenocarcinoma neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Fox Chase Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

  • Honor Health

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • NEXT Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.